Genesis Energy (GNE) H2 2024 earnings summary

Executive summary

• FY24 was challenging due to adverse hydrology, gas supply constraints, unplanned outages, and a structural gas shortage, but strategic objectives under Gen35 and the 8 by '28 framework were delivered, demonstrating portfolio resilience.

• Customer numbers grew 2.7% to 496,596, and employee engagement remained 6% above the national benchmark at 81%, despite significant organizational change.

• Major progress was made in renewables, including financial close on Lauriston Solar Farm, acquisition of the Edgecumbe solar asset (127 MW), and expansion of the solar pipeline.

• The company advanced its transition to a lower-cost, lighter-touch retail model, reducing 130 FTE, and invested in technology and team capabilities.

• Strategic investments included the Lauriston Solar JV (63 MWp), Edgecumbe Solar (127 MWp), and a 100 MW/200 MWh battery at Huntly, with FID reached and installation starting FY25.

Financial highlights

• Revenue increased 28% year-over-year to $3.1 billion, driven by higher wholesale prices and retail momentum, especially in C&I.

• EBITDAF was $407.2 million, down 22% from FY23; NPAT fell 33% to $131.1 million.

• Gross margin declined 10% to $770.3 million due to higher generation costs and lower hydro output.

• Operating costs rose 10% to $363.1 million, above inflation but in line with strategic investment plans.

• Final dividend declared at 7.0 cps, totaling 14.0 cps for the year, down 21% year-over-year, maintaining a yield around 9%.

• Insurance settlement of $29.4 million for Huntly Unit 5 outage included in other revenue.

• Kupe segment gross margin dropped due to lower production and a planned outage; a $64 million impairment was recognized after reserve revision.

Outlook and guidance

• FY25 EBITDAF guidance is around $460 million, with capital expenditure expected at $180 million and OpEx at $390 million.

• Earnings guidance is subject to volatility in electricity and gas markets, gas and plant availability, hydrology, and adverse events.

• Strategic focus is on delivering "Eight by 2028" objectives, targeting mid-500s EBITDAF by FY28.